Antisense oligonucletide modulation of tumor necrosis factor-alpha (TNF-alpha) expression

Details for Australian Patent Application No. 2002313389 (hide)

Owner Isis Pharmaceuticals, Inc.

Inventors Not Given

Pub. Number AU-A-2002313389

Parent 62903

Filing date 2 December 2002

Wipo publication date 20 March 2003

International Classifications

C12Q 001/68 Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

C12N 015/00 Mutation or genetic engineering

A61K 048/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

C07H 021/04 Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Event Publications

2 January 2003 Complete Application Filed

20 March 2003 Application Open to Public Inspection

  Published as AU-A-2002313389

30 June 2005 Amendment Made

  The nature of the amendment is: Add co-inventor names Baker, Brenda F.; Bennett, Frank C.; Butler, Madeline M.; Shanahan JR, William J.

18 May 2006 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002313390-An anchorable guidewire system

2002313388-Protease conjugates